Company announces new board and business development appointments
25th February 2014
Cambridge, MA – CluePoints, a leading provider of Risk-Based Monitoring (RBM) solutions for clinical trials, has announced three new appointments to its global team. John Colby and Elizabeth Polvent join the company’s U.S business development team, fulfilling a key element in its strategy for growth, while CluePoints also welcomes Jean Stéphenne, President of the Board of Directors of GlaxoSmithKline Biologicals, as a member of its board.
John Colby joins CluePoints as Senior Director of Business Development on the East Coast U.S, providing strategic leadership and driving business growth in the geography. Previously of Aptiv Solutions and PRA International, John brings a strong track record of managing strategic relationships in the clinical trials industry. Elizabeth Povent has been named as the company’s Director of Business Development on the West Coast. Based in California, she has more than 10 years’ Clinical Operations experience in the industry with her most recent roles serving as the key liaison on Federally funded clinical trials, as well as overseeing early-phase clinical development programs. She joins CluePoints to support the growth of the business’ footprint and to establish long-term partnerships with key customers in the region.
In addition to strengthening its business development team, CluePoints has announced that Jean Stéphenne has joined the company’s board of directors. Jean joined SmithKline-RIT (now GSK Biologicals) in 1974 as head of bacterial and viral vaccines production. Through various executive management positions within the company, he has led GSK’s global vaccines business since 1988. From March 2010 to April 2012, he was appointed as the Chairman and President of GSK Biologicals. Jean currently serves as a Special Advisor to the CEO at GSK, is a member of the Corporate Executive Team (GSK Group), as well as President of the Board of Directors of GSK Biologicals.
“CluePoints is at a very exciting time in its development with increasing demand for its solutions as a result of growing regulatory support for practical Risk-Based Monitoring techniques,” comments Jean Stéphenne. He adds, “With a steadily growing global reputation for delivering scientific excellence and innovation, CluePoints is making its mark on the industry and I am delighted to be joining the company’s board and look forward to the opportunity to help build on its achievements.”
Francois Torche, CEO of CluePoints, comments: “I am delighted to announce the three new additions to our global team. In 2014 CluePoints is focused on fulfilling demand in growing markets and achieving new levels of innovation for customers. I believe the insights and experience of each of these new appointments will be invaluable in our ongoing development.”
For further information on CluePoints solutions, please visit www.cluepoints.com
CluePoints® is a Central Statistical Monitoring solution that has been designed and perfected over the last 10 years. It employs unique statistical algorithms to determine the quality, accuracy and integrity of clinical trial data both during and after study conduct. Aligned with guidance from the FDA and EMA, CluePoints® is deployed to support traditional on-site monitoring and can be implemented as the engine to drive a Risk-Based Monitoring strategy. The value of using CluePoints® lies in its powerful and timely ability to identify anomalous data and site errors allowing improvement in clinical data quality, optimisation of on-site monitoring and a significant reduction in overall regulatory submission risk.
Chief Commercial Officer, CluePoints